Substudy 1 -FRα-expressing, HRD proficient, Ovarian w/ no progression or immediately after front-line or 2L plat-based chemo.
MIRV w/ Bevacizumab vs Bevacizumab alone as maintenance
Substudy 2 – FRα expressing, 2/3 line, plat sensitive, high-grade serous Ovarian, FT, or PP carcinoma.
MIRV w/carbo followed by MRIV monotherapy
